It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Lähteenvuo notes that while more research is called for, drugs like Ozempic may offer hope to those burdened by addiction, ...
After years of shortages, the Food and Drug Administration (FDA) has now listed Novo Nordisk’s blockbuster diabetes and ...
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians can combine, mix, or adjust the ingredients of a medication — to meet ...
A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...